GlycoVaxyn and a Harvard University affiliated hospital receive USD 3.4 million NIH grant for Staphylococcus aureus vaccine

06-May-2010 - Switzerland

GlycoVaxyn AG and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women’s Hospital, Harvard Medical School, announced that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine.

Using GlycoVaxyn’s proprietary technology, staphylococcal surface polysaccharides will be conjugated in vivo to conserved protein antigens from S. aureus. The efficacy of this novel bioconjugate vaccine will then be evaluated in different animal models of S. aureus infection.

“GlycoVaxyn’s first generation S. aureus bioconjugate vaccine has shown protective efficacy in preclinical studies. The new generation vaccine is expected to give broader protection against a variety of S. aureus strains,” declared Dr. Jean Lee.

GlycoVaxyn and the Brigham and Women’s Hospital have a long standing collaboration on this project, and the NIH funding will accelerate the development of potential vaccine candidates.

GlycoVaxyn, which started Phase I clinical trials with a bioconjugate vaccine against Shigella dysenteriae early this year, is expecting to start a clinical trial with its first generation S. aureus vaccine by late 2011.

“Our bioconjugation technology allows us a very flexible and powerful approach to multivalent vaccine development, coupling polysaccharide to protein antigens in a strictly controlled way,” said Dr. Michael Wacker, CSO and founder of GlycoVaxyn. “This grant confirms the potential of this approach and will allow extensive preclinical evaluation of the novel vaccine.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Saline water better than soap and water for cleaning wounds, researchers find

Activity of 2 genes will inform anti-cancer drug prescription - Gene expression to guide cancer drug prescription

Activity of 2 genes will inform anti-cancer drug prescription - Gene expression to guide cancer drug prescription

Prion disease detected soon after infection and in surprising place in mouse brains

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

A type of virus present in the gut microbiota is associated with better cognitive ability in humans, mice and flies - The study finds a greater presence of these viruses in people who eat dairy products in their regular diet

Study in Spain and Romania confirms radon as second leading cause of lung cancer

Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

Sartorius closes acquisition of selected assets of Danaher Life Sciences - Broadens portfolio for the development and production of biotech medicines

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

EMA starts rolling review of COVID-19 vaccine Vidprevtyn - Protein-based vaccine developed by Sanofi Pasteur

Researchers use sugar to halt esophageal cancer in its tracks

Anika Therapeutics Announces Termination of Worldwide Development and Commercialization Partnership with OrthoNeutrogena - Company Files Pre-Market Approval Applicaton for Cosmetic Tissue Augmentation Product

Scottish Life Sciences Sector set to Benefit from South Korean Institute Opening in Glasgow

Endotis Pharma forms a strategic alliance with Catalent Pharma Solutions for the development of synthetic oligosaccharides